Discovery of a potent small molecule IL-2 inhibitor through fragment assembly
- J Am Chem Soc. 2003 Apr 2;125(13):3714-5. doi: 10.1021/ja034247i.
- 1. Sunesis Pharmaceuticals, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA. [email protected]
Using a site-directed fragment discovery method called tethering, we have identified a 60 nM small molecule antagonist of a cytokine/receptor interaction (IL-2/IL2Ralpha) with cell-based activity. Starting with a low micromolar hit, we employed a combination of tethering, structural biology, and computational analysis to design a focused set of 20 compounds. Eight of these compounds were at least 5-fold more active than the original hit. One of these compounds showed a 50-fold enhancement and represents the highest affinity inhibitor reported against this protein-protein target class. This method of coupling selected fragments with a low micromolar hit shows great potential for generating high-affinity lead compounds.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Interleukin RelatedResearch Areas: Inflammation/Immunology
-
target: Interleukin RelatedResearch Areas: Inflammation/Immunology